This article is more than 5 years old. Information may no longer be current.
VIDEO: CVD prevention looks promising with positive new data
ORLANDO, Fla. — Sameer Bansilal, MD, MS, of the Icahn School of Medicine at Mount Sinai, discusses new research in the arena of CVD prevention revealed at the annual American Heart Association Scientific Sessions.
“Truly, the time for prevention has come,” he said.
Bansilal highlights positive outcomes on CV risk factors in the Fifty-Fifty Program looking at monthly peer group therapy, as well as improvements in smoking abstinence in a study investigating varenicline (Chantix, Pfizer) to treat high-risk patients hospitalized for ACS.
He touches on the LDL lowering seen in MI-GENES when CVD risk was disclosed to patients through genetic risk information for CHD, along with lifestyle changes observed with mobile health technology offering “feedback in real time.”
Bansilal also shares findings from the PROMISE trial, in which patients were triaged with an anatomical vs. functional tests, on fruit and vegetable intake, physical activity and BMI.
“These studies dovetailed with each other nicely in terms of what we need to do at this time for improving lifestyle,” Bansilal said.
Lastly, he details the benefits seen among patients with diabetes treated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) in the EMPA-REG Outcome study, including HF, hospitalizations and mortality.